top of page

Search
BioTech Scaling Vault
Exclusive strategy memos for biotech founders, CEOs, and scaling operators. Each memo delivers clear, no-BS insights on building systems, raising investor confidence, and scaling teams without breaking operations. Designed for leaders who need focused guidance, not theory.


Why Biotech Process Documentation Separates Scalable Companies from Lucky Ones
Most biotech teams confuse fast progress with real scalability. Without documented processes, growth relies on luck, not systems. Here’s why every successful biotech operator turns chaos into clarity through process documentation.

Attila Foris
Oct 142 min read


Scaling Framework for Biotech: The 3 Blind Spots That Stall Growth
Most biotech CEOs fail not on science, but on scale. This expanded framework reveals the three blind spots—pipeline chaos, headcount traps, and investor readiness—that stall growth.

Attila Foris
Oct 143 min read


The Continuous Experiment Engine
Most biotech CEOs act like science is a lottery. The edge isn’t predicting biology—it’s running unlimited, budget-disciplined experiments. This memo outlines why building a Continuous Experiment Engine is now the only viable path to scale, investor readiness, and a genuine competitive advantage.

Attila Foris
Oct 33 min read


Scaling Biotech Operations: Investors Now Judge Execution, Not Just Science
Investors in 2025 aren’t just backing biotech science—they’re judging execution. CEOs who can’t show scaling signals—operational rhythm, cross-team clarity, and a real scalability narrative—risk burning credibility, not just capital. This memo breaks down the three signals biotech leaders must master to win trust and funding.

Attila Foris
Oct 12 min read


Biotech Scaling Operations: The Hidden Breakpoint CEOs Ignore
Biotech CEOs don’t fail because the science breaks. They fail because operations can’t scale. Here’s why operational discipline, not IP, determines who raises at Series B and beyond.

Attila Foris
Sep 302 min read
bottom of page
